Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Biocatalyst product sales	$ 1,818	$ 2,562	$ 6,915	$ 8,323
Biocatalyst research and development	14,517	3,364	19,247	7,176
Revenue sharing arrangement	1,066	1,546	4,056	5,617
Total revenues	17,401	7,472	30,218	21,116
Costs and operating expenses:
Cost of biocatalyst product sales	1,302	1,532	4,009	6,179
Research and development	4,994	5,038	15,457	17,708
Selling, general and administrative	5,415	5,157	16,289	16,791
Total costs and operating expenses	11,711	11,727	35,755	40,678
Income (loss) from operations	5,690	(4,255)	(5,537)	(19,562)
Interest income	4	3	12	15
Other expenses	(26)	(57)	(147)	(183)
Income (loss) before income taxes	5,668	(4,309)	(5,672)	(19,730)
Provision for (benefit from) income taxes	274	253	(144)	(314)
Net income (loss)	$ 5,394	$ (4,562)	$ (5,528)	$ (19,416)
Net income (loss) per share, basic (dollars per share)	$ 0.14	$ (0.12)	$ (0.14)	$ (0.51)
Net income (loss) per share, diluted (dollars per share)	$ 0.13	$ (0.12)	$ (0.14)	$ (0.51)
Weighted average common shares used in computing net income (loss) per share, basic (shares)	39,767	38,450	39,340	38,063
Weighted average common shares used in computing net income (loss) per share, diluted (shares)	40,970	38,450	39,340	38,063